On the Origins of the Androgen Receptor Low Molecular Weight Species

Maria Mudryj, Clifford G Tepper

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Prostate cancer (CaP), a commonly diagnosed malignancy, is readily treated by androgen ablation. This treatment temporarily halts the disease, but castration-resistant neoplasms that are refractory to current therapies emerge. While these neoplasms are no longer dependent on physiological levels of androgens, they remain reliant on the expression of the androgen receptor (AR). There are multiple mechanisms by which CaP cells circumvent androgen ablation therapies. These include AR mutations that broaden ligand specificity, AR overexpression, AR activation by growth factors and cytokines, overexpression of AR co-activators, altered steroid metabolism, and a locus-wide histone transcriptional activation of some AR targets. This review focuses on a more recently described mechanism: the expression of low molecular weight AR species that are missing the ligand-binding domain and function independently of ligand to drive proliferation. The etiology, biological activity, unique features, predictive value, and therapeutic implication of these androgen receptor isoforms are discussed in depth.

Original languageEnglish (US)
Pages (from-to)259-269
Number of pages11
JournalHormones and Cancer
Issue number5
StatePublished - Oct 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems


Dive into the research topics of 'On the Origins of the Androgen Receptor Low Molecular Weight Species'. Together they form a unique fingerprint.

Cite this